Decitabine suppresses tumor growth by activating mouse mammary tumor virus and interferon-β pathways

Authors

  • Ryan Johnson Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • Andrew Brola Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA https://orcid.org/0009-0005-0033-5526
  • Cade Wycoff Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • William Wycoff Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • Seth Neumeyer Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA https://orcid.org/0009-0003-2251-9444
  • Richard Tuttle Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • Sarah Light Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • Jiayi Li Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • Stephen Christensen Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA
  • Yingguang Liu Department of Biomedical Sciences, College of Osteopathic Medicine, Liberty University, Lynchburg, VA, USA

DOI:

https://doi.org/10.17305/bb.2025.12852

Keywords:

Decitabine , DNA methyltransferase inhibitor, mouse mammary tumor virus, interferon, tumor, cancer, 4T1, MC38, interferon regulatory factor 7

Abstract

Decitabine (DAC), a DNA methyltransferase inhibitor (DNMTi), is clinically effective in hematological malignancies such as myelodysplastic syndrome and acute myeloid leukemia, but its precise antineoplastic mechanisms remain incompletely understood. Beyond promoter demethylation, DAC is known to activate endogenous retroviruses (ERVs) and trigger type I interferon (IFN-I) responses, a phenomenon known as viral mimicry. The aim of this study was to investigate the roles of the mouse mammary tumor virus (MMTV) and interferon-β (IFN-β) in DAC-mediated tumor suppression. We employed two murine tumor models—4T1 mammary carcinoma and MC38 colon adenocarcinoma—in syngeneic immunocompetent mice, immunodeficient nude mice, and in vitro cultures. RNA and protein expression were assessed by quantitative PCR and immunoblotting, while functional contributions of MMTV and IFN-β were tested using short hairpin RNA (shRNA) knockdowns. DAC treatment suppressed tumor growth and pulmonary metastasis in vivo and inhibited cancer cell proliferation in vitro. It induced transcription of MMTV and expression of IFN-β, with a strong negative correlation between MMTV Env protein levels and tumor mass. Knockdown of either MMTV or IFN-β conferred resistance to DAC, confirming their functional roles. Reciprocal regulation was observed: MMTV knockdown reduced IFN-β expression, while IFN-β knockdown increased MMTV Env accumulation. Furthermore, DAC upregulated interferon regulatory factor 7 (IRF7), but this effect declined during prolonged treatment, suggesting a temporally restricted therapeutic window. In conclusion, our findings provide in vivo support for the viral mimicry hypothesis and demonstrate that MMTV and IFN-β contribute to DAC-mediated tumor suppression. The observed IRF7 downregulation and potential induction of immune checkpoints highlight the importance of therapeutic strategies combining DNMTis with immune checkpoint blockade to sustain antineoplastic efficacy.

 

Citations

Downloads

Download data is not yet available.
Decitabine suppresses tumor growth by activating mouse mammary tumor virus and interferon-β pathways

Published

27-08-2025

How to Cite

1.
Decitabine suppresses tumor growth by activating mouse mammary tumor virus and interferon-β pathways. Biomol Biomed [Internet]. 2025 Aug. 27 [cited 2025 Sep. 1];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12852